SOFIE opens 20,000 square-foot theranostics facility in New Jersey

by John R. Fischer, Senior Reporter | May 04, 2022
Business Affairs Molecular Imaging Rad Oncology Proton Therapy

The company previously expanded its reach when it acquired Cyclotope Radiopharmacy from Houston Cyclotron Partners back in 2019. The deal brought the number of radiopharmacies under SOFIE’s control to 17, and the company planned to expand into five additional markets over the next two years.

Originally Sofie Biosciences, the company rebranded in 2017 when it acquired Zevacor Pharma and its 16 radiopharmacies and contract manufacturing organization. The agreement supported clinical trials with the imaging and radiochemistry products of Sofie Biosciences, allowing both organizations to offer both clinical and life science services.

In addition to new theranostics, the two companies saw potential in FDG and expected it to continue to grow due to the use of FDG PET in treatment monitoring. They also expected that more studies on amyloid PET imaging in patient management for Alzheimer’s disease would help spur the growth of amyloid imaging.

Back to HCB News

You Must Be Logged In To Post A Comment